Home Recalls D-0185-2024
Class II · Moderate risk Terminated Initiated Jan 26, 2022 (5 years ago)
Jardiance (empagliflozin tablets), 25 mg, 30 tablets (3 blister cards with 10 tablets…
Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.
Why it was recalled
CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.
What was recalled
Jardiance (empagliflozin tablets), 25 mg, 30 tablets (3 blister cards with 10 tablets each), Rx only, Distributed by: Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877. NDC: 0597-0153-37
Recalling firm Cardinal Healthcare
Origin OH, United States
Initiated by Voluntary: Firm initiated
FDA recall number D-0185-2024
What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.
Other Empagliflozin recalls
See all
Class II · Moderate risk Ongoing Jun 12, 2026
Reason CGMP Deviations: An incorrect detergent was used and the required swab sampling was not performed on a production hopper that had previously been…
Class II · Moderate risk Terminated Mar 9, 2023
Reason Labeling: Label Mix-up
Class II · Moderate risk Terminated Mar 15, 2021
Reason CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Class II · Moderate risk Terminated Mar 15, 2021
Reason CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Class II · Moderate risk Terminated Mar 15, 2021
Reason CGMP Deviations: Intermittent exposure to temperature excursion during storage.